Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
37
KRRO Quote, Financials, Valuation and Earnings
Last price:
$8.39
Seasonality move
:
-28.04%
Day range:
$7.89 - $8.54
52-week range:
$5.20 - $55.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.45x
P/B ratio:
0.78x
Volume:
217K
Avg. volume:
860.5K
1-year change:
-81.2%
Market cap:
$77.3M
Revenue:
$2.3M
EPS (TTM):
-$9.42
Analysts' Opinion
-
Consensus RatingKorro Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $93.88, Korro Bio, Inc. has an estimated upside of 5.56% from its current price of $8.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $8.21.
Fair Value
-
According to the consensus of 6 analysts, Korro Bio, Inc. has 5.56% upside to fair value with a price target of $93.88 per share.
KRRO vs. S&P 500
-
Over the past 5 trading days, Korro Bio, Inc. has overperformed the S&P 500 by 0.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Korro Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Korro Bio, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Korro Bio, Inc. reported revenues of $1.1M.
Earnings Growth
-
Korro Bio, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Korro Bio, Inc. reported earnings per share of -$1.92.
Enterprise value:
28.5M
EV / Invested capital:
0.20x
Price / LTM sales:
10.45x
EV / EBIT:
--
EV / Revenue:
3.87x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.5M
Return On Assets:
-43.6%
Net Income Margin (TTM):
-1199.53%
Return On Equity:
-63.78%
Return On Invested Capital:
-48.36%
Operating Margin:
-1764.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $7.4M | -- | $1.1M | |
| Gross Profit | -$3.9M | -$4.1M | $2.5M | -$865K | -$110K | |
| Operating Income | -$76.6M | -$108.4M | -$94.5M | -$23.3M | -$19.2M | |
| EBITDA | -$72.7M | -$104.3M | -$89.6M | -$22.4M | -$18M | |
| Diluted EPS | -$225.73 | -$12.02 | -$9.42 | -$2.26 | -$1.92 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $149.9M | $101M | $42.5M | $152.8M | $98.2M | |
| Total Assets | $202.2M | $136M | $46.3M | $243.5M | $161.6M | |
| Current Liabilities | $10.5M | $20M | $9.6M | $13.6M | $14.6M | |
| Total Liabilities | $55.1M | $54M | $9.6M | $63.9M | $62.5M | |
| Total Equity | $147.1M | $82M | $36.7M | $179.6M | $99M | |
| Total Debt | $44.3M | $42.3M | -- | $41.8M | $41.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$57.2M | -$73.7M | -$68.4M | -$16.1M | -$17.2M | |
| Cash From Investing | $17.3M | -$122.2M | $26.3M | -$12.6M | $7.6M | |
| Cash From Financing | $42.9M | $213M | $1.2M | $728K | $128K | |
| Free Cash Flow | -$68.6M | -$91.8M | -$70.2M | -$21M | -$17.4M | |
KRRO
Sector
Market Cap
$77.3M
$28.4M
Price % of 52-Week High
14.69%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-0.55%
-1.49%
1-Year Price Total Return
-81.2%
-16.67%
Beta (5-Year)
3.030
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.02
200-day SMA
Sell
Level
$20.54
Bollinger Bands (100)
Sell
Level
11.06 - 40.08
Chaikin Money Flow
Sell
Level
-5.5M
20-day SMA
Buy
Level
$7.01
Relative Strength Index (RSI14)
Sell
Level
34.80
ADX Line
Sell
Level
34.52
Williams %R
Sell
Level
-17.2199
50-day SMA
Sell
Level
$21.67
MACD (12, 26)
Sell
Level
-3.02
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-3.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8921)
Sell
CA Score
(Annual)
Level (-1.2216)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.3688)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, KRRO has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KRRO average analyst price target in the past 3 months is $93.88.
-
Where Will Korro Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Korro Bio, Inc. share price will rise to $93.88 per share over the next 12 months.
-
What Do Analysts Say About Korro Bio, Inc.?
Analysts are divided on their view about Korro Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Korro Bio, Inc. is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Korro Bio, Inc.'s Price Target?
The price target for Korro Bio, Inc. over the next 1-year time period is forecast to be $93.88 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KRRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Korro Bio, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KRRO?
You can purchase shares of Korro Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Korro Bio, Inc. shares.
-
What Is The Korro Bio, Inc. Share Price Today?
Korro Bio, Inc. was last trading at $8.39 per share. This represents the most recent stock quote for Korro Bio, Inc.. Yesterday, Korro Bio, Inc. closed at $8.21 per share.
-
How To Buy Korro Bio, Inc. Stock Online?
In order to purchase Korro Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KRRO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KRRO
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
0.78x
1.81x
Price / LTM sales
10.45x
1.58x
Growth Metrics
KRRO
Sector
Revenue growth
--
4.62%
Earnings growth
14.8%
10.7%
Revenue (5-year growth)
-39.89%
6.5%
Earnings forecast
-$2.68
-$0.21
Profitability
KRRO
Sector
Profitability FY 2024
-$1.3M
$3.6M
Return on invested capital
-48.36%
-31.84%
Return on assets
-43.6%
-27.96%
Return on equity
-63.78%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
11
Balance Sheet
KRRO
Sector
Total cash
$93.5M
$26.4M
Short term investments
$70.5M
$25.7M
Total assets
$226.2M
$76.9M
Long term debt
$41.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.27% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
